Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Bone metastases

2

Unknown

2,578

Pain

614

Cancer

592

Hypertension

567

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1993

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Palliative

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

DAILYMED

2

DRUG BANK

2

EVMPD

2

FDA UNII

2

NDF-RT

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

VARIOUS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

THERAPEUTIC RADIOPHARMACEUTICALS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

PAIN PALLIATION (BONE SEEKING AGENTS)

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Various pain palliation radiopharmaceuticals

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

STRONTIUM CATION SR-89

06A33308KH

Export Data
Search for Structure

Status:

US Approved Rx (2003)

First approved in 1993

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

Bone metastases

Strontium SR-89 is a radioactive isotope of strontium. Strontium-89 decays by beta emission with a half-life of 50.5 days. Beta-particles produced by radioactive decay penetrate tissues at a range of approximately 8 mm. Strontium SR-89 is used in med...

icine for the relief of bone pain in patients with painful skeletal metastases. Following intravenous injection, soluble strontium compounds behave like their calcium analogs, clearing rapidly from the blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone.

STRONTIUM CHLORIDE SR-89

5R78837D4A

Export Data
Search for Structure

Status:

US Approved Rx (2003)

First approved in 1993

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

Bone metastases

Strontium SR-89 is a radioactive isotope of strontium. Strontium-89 decays by beta emission with a half-life of 50.5 days. Beta-particles produced by radioactive decay penetrate tissues at a range of approximately 8 mm. Strontium SR-89 is used in med...

icine for the relief of bone pain in patients with painful skeletal metastases. Following intravenous injection, soluble strontium compounds behave like their calcium analogs, clearing rapidly from the blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1